| Autor: |
CHEN Long, LIU Yujie, TIAN Suqing, WANG Cuiying, HE Donglei |
| Jazyk: |
čínština |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Zhongliu Fangzhi Yanjiu, Vol 49, Iss 1, Pp 53-57 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1000-8578 |
| DOI: |
10.3971/j.issn.1000-8578.2022.21.0794 |
| Popis: |
Objective To compare curative effect between lenvatinib combined with locoregional therapy and locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng's classification. Methods The patients in lenvatinib combined with locoregional therapy group received orally-administered lenvatinib at a dose of 12 mg qd for patients≥60 kg or 8 mg qd for patients < 60 kg. The locoregional therapy group only received locoregional therapy. We retrospectively analyzed the clinical data and prognosis of two groups. Results The CR+PR were 78.1% and 53.6% in the combination group and locoregional therapy group, respectively (P < 0.05). The response rate, disease control rate and overall survival of the combination group were higher than those in the locoregional therapy group (P < 0.05). Conclusion The curative effect and overall survival of lenvatinib combined with locoregional therapy is better than locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng's classification. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
